Financial Survey: BioRestorative Therapies (NASDAQ:BRTX) vs. NewGenIvf Group (NASDAQ:NIVF)

NewGenIvf Group (NASDAQ:NIVF) and BioRestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Valuation & Earnings

This table compares NewGenIvf Group and BioRestorative Therapies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$5.14 million	0.49	$130,000.00	N/A	N/A
BioRestorative Therapies	$174,100.00	63.31	-$14.41 million	($2.31)	-0.70

NewGenIvf Group has higher revenue and earnings than BioRestorative Therapies.

Analyst Recommendations

This is a summary of recent ratings for NewGenIvf Group and BioRestorative Therapies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	0	0	0	0	N/A
BioRestorative Therapies	0	0	1	0	3.00

BioRestorative Therapies has a consensus target price of $18.00, suggesting a potential upside of 1,005.65%. Given BioRestorative Therapies’ higher probable upside, analysts clearly believe BioRestorative Therapies is more favorable than NewGenIvf Group.

Profitability

This table compares NewGenIvf Group and BioRestorative Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
BioRestorative Therapies	-6,898.28%	-107.65%	-88.32%

Volatility and Risk

NewGenIvf Group has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 63.02, meaning that its stock price is 6,202% more volatile than the S&P 500.

Institutional and Insider Ownership

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 69.4% of BioRestorative Therapies shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Comparatively, 21.6% of BioRestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

NewGenIvf Group beats BioRestorative Therapies on 6 of the 11 factors compared between the two stocks.

About NewGenIvf Group

A SPAC I Acquisition Corp. is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or related business combination with one or more businesses. A SPAC I Acquisition Corp. is based in Singapore.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.